{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:06:20Z","timestamp":1760043980951,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pbb.2020.172972","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T21:31:36Z","timestamp":1592429496000},"page":"172972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats"],"prefix":"10.1016","volume":"196","author":[{"given":"Misae","family":"Takakuwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meguru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Anabuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pbb.2020.172972_bb0005","doi-asserted-by":"crossref","first-page":"e00241","DOI":"10.1002\/prp2.241","volume":"4","author":"Arakawa","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"3","key":"10.1016\/j.pbb.2020.172972_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2967\/jnumed.108.056374","article-title":"Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards","volume":"50","author":"Bao","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.pbb.2020.172972_bb0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2020.172972_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","article-title":"NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update","volume":"142","author":"Cadinu","year":"2018","journal-title":"Neuropharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2020.172972_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","article-title":"Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains","volume":"75","author":"Citrome","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.pbb.2020.172972_bb0030","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","article-title":"Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review","volume":"15","author":"De Hert","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pbb.2020.172972_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2017.01.016","article-title":"In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects","volume":"117","author":"Delnomdedieu","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2020.172972_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2017.05.009","article-title":"Challenges and opportunities for the development of new antipsychotic drugs","volume":"143","author":"Forray","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"26","key":"10.1016\/j.pbb.2020.172972_bb0045","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.pbb.2020.172972_bb0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14737175.2017.1268531","article-title":"Phosphodiesterase 10 inhibitors in clinical development for CNS disorders","volume":"17","author":"Geerts","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2020.172972_bb0055","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0060","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.pbb.2020.172972_bb0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0166-2236(90)90104-I","article-title":"Neurotransmitters and neuromodulators in the basal ganglia","volume":"13","author":"Graybiel","year":"1990","journal-title":"Trends Neurosci."},{"issue":"14","key":"10.1016\/j.pbb.2020.172972_bb0070","doi-asserted-by":"crossref","first-page":"R509","DOI":"10.1016\/S0960-9822(00)00593-5","article-title":"The basal ganglia","volume":"10","author":"Graybiel","year":"2000","journal-title":"Curr. Biol."},{"issue":"Suppl. 4","key":"10.1016\/j.pbb.2020.172972_bb0075","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0924-977X(01)00109-2","article-title":"Extrapyramidal side effects are unacceptable","volume":"11","author":"Kane","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2020.172972_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543776.2012.739157","article-title":"Phosphodiesterase 10A inhibitors: a 2009\u20132012 patent update","volume":"23","author":"Kehler","year":"2013","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"15","key":"10.1016\/j.pbb.2020.172972_bb0090","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/j.bmc.2019.06.021","article-title":"Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety","volume":"27","author":"Koizumi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.pbb.2020.172972_bb0095","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14656566.7.8.1005","article-title":"Current schizophrenia drugs: efficacy and side effects","volume":"7","author":"Krebs","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"issue":"S1","key":"10.1016\/j.pbb.2020.172972_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS spectrums"},{"issue":"3 Pt 1","key":"10.1016\/j.pbb.2020.172972_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"issue":"9657","key":"10.1016\/j.pbb.2020.172972_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2020.172972_bb0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2019","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00259-019-04488-0","article-title":"Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development","volume":"47","author":"McCluskey","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.pbb.2020.172972_bb0125","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","article-title":"Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate)","volume":"26","author":"Morimoto","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"10039","key":"10.1016\/j.pbb.2020.172972_bb0130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pbb.2020.172972_bb0135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2967\/jnumed.113.131409","article-title":"Phosphodiesterase 10A PET radioligand development program: from pig to human","volume":"55","author":"Plisson","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.pbb.2020.172972_bb0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0929867043456043","article-title":"New antipsychotics and schizophrenia: a review on efficacy and side effects","volume":"11","author":"Serretti","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2020.172972_bb0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"31","key":"10.1016\/j.pbb.2020.172972_bb0160","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2174\/1381612819666131216115417","article-title":"Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment","volume":"20","author":"Snyder","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pbb.2020.172972_bb0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-3-319-58811-7_14","article-title":"PDE inhibitors for the treatment of schizophrenia","volume":"17","author":"Snyder","year":"2017","journal-title":"Adv Neurobiol"},{"issue":"12","key":"10.1016\/j.pbb.2020.172972_bb0170","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.pbb.2020.172972_bb0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2020.172972_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","article-title":"In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents","volume":"352","author":"Suzuki","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"16","key":"10.1016\/j.pbb.2020.172972_bb0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2174\/1389450120666190801114210","article-title":"Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 2: focus on schizophrenia","volume":"20","author":"Swierczek","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.pbb.2020.172972_bb0190","doi-asserted-by":"crossref","first-page":"172757","DOI":"10.1016\/j.pbb.2019.172757","article-title":"Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents","volume":"185","author":"Takakuwa","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2020.172972_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuroimage.2016.06.047","article-title":"A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor","volume":"141","author":"Takano","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.pbb.2020.172972_bb0200","first-page":"69","article-title":"Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme","volume":"10","author":"Thompson","year":"1979","journal-title":"Adv Cyclic Nucleotide Res"},{"issue":"8","key":"10.1016\/j.pbb.2020.172972_bb0205","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.pbb.2020.172972_bb0210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","article-title":"Conditioned avoidance response in the development of new antipsychotics","volume":"16","author":"Wadenberg","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pbb.2020.172972_bb0215","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0920-9964(14)70069-6","article-title":"Early clinical results of the phosphodiesterase 10 inhibitor OMS643762 in development for the treatment of schizophrenia and Huntington\u2019s disease","volume":"153","author":"Yu","year":"2014","journal-title":"Schizophr. Res."},{"issue":"29","key":"10.1016\/j.pbb.2020.172972_bb0220","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","article-title":"Phosphodiesterase 10 inhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery","volume":"25","author":"Zagorska","year":"2018","journal-title":"Curr. Med. Chem."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720302239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720302239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:37:18Z","timestamp":1758775038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305720302239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":44,"alternative-id":["S0091305720302239"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172972","relation":{},"ISSN":["0091-3057"],"issn-type":[{"type":"print","value":"0091-3057"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172972"}}